Various FDA Approved Radiopharmaceuticals

The Department of the Army Medical Command has issued a Special Notice regarding the procurement of various FDA-approved radiopharmaceuticals through the Medical Readiness Contracting Office-West. This notice announces the government's intent to award a sole source contract to PETNET Solutions for the supply of multiple radiopharmaceuticals including FDG, NaF, Amyvid, Axumin, Cerianna, Posluma, and Tauvid. The procurement is being conducted under the authority of 10 United States Code 3204(a)(1), which permits sole source awards when only one responsible source can satisfy the agency's requirements. The contract will be structured as a Firm Fixed-Price call order arrangement with a performance period extending from October 1, 2025, through September 30, 2026. This procurement falls under NAICS code 325412 for Pharmaceutical Preparation Manufacturing with a size standard of 1,300 employees.

The primary objective of this Special Notice is to formally announce the government's intention to proceed with a non-competitive sole source procurement, providing transparency to the contracting community while indicating that competition will not be pursued for this requirement. The solicitation is scheduled for award on or about September 15, 2025, with responses to this notice due by July 25, 2025. The government has explicitly stated that it will not accept capability briefings or telephonic inquiries regarding this procurement, maintaining full discretion over any decisions regarding competition. Contractors interested in this opportunity must recognize that the government has determined PETNET Solutions is the only responsible source capable of meeting their specific radiopharmaceutical requirements. The notice serves as the required advance notification for sole source procurements, allowing potential contractors to understand the government's procurement strategy while emphasizing that no competitive opportunities will be available for this particular requirement.